Drug Profile
Research programme: p38 MAP kinase inhibitors - Amphora
Latest Information Update: 18 Apr 2007
Price :
$50
*
At a glance
- Originator Amphora Discovery Corporation
- Class
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 17 Jan 2005 Amphora Discovery Corporation and Ortho-McNeil Pharmaceutical have entered into a research collaboration regarding anti-inflammatory drugs
- 26 Aug 2004 Preclinical trials in Inflammation in USA (unspecified route)